- Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
- Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
- Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
- Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
- Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant
- Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
- Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
- Belite Bio Announces $25 Million Registered Direct Offering
- Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
- Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
More ▼
Key statistics
On Thursday, Belite Bio Inc (BLTE:NAQ) closed at 45.57, -6.23% below its 52-week high of 48.60, set on Feb 12, 2024.
52-week range
Open | 44.90 |
---|---|
High | 45.60 |
Low | 44.38 |
Bid | 39.57 |
Offer | 45.65 |
Previous close | 45.03 |
Average volume | 48.78k |
---|---|
Shares outstanding | 30.40m |
Free float | 306.33k |
P/E (TTM) | -- |
Market cap | 1.37bn USD |
EPS (TTM) | -1.18 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼